The deal is subject to customary closing requirements and Myriad expects the transaction to close in its fiscal second quarter. About Castle Biosciences Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. The company's tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. Castle Biosciences believes that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information. About Myriad Genetics Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease.